1
|
Ivanic MG, Oulee A, Norden A, Javadi SS, Gold MH, Wu JJ. Neurogenic Rosacea Treatment: A Literature Review. J Drugs Dermatol 2023; 22:566-575. [PMID: 37276164 DOI: 10.36849/jdd.7181] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
Rosacea is a chronic skin disorder involving central facial erythema secondary to vascular instability and cutaneous inflammation. Rosacea is divided into different subtypes based on the morphology of the rash — erythematotelangiectatic, papulopustular, phymatous, and ocular rosacea. A less-known subtype called neurogenic rosacea has been proposed to categorize patients suffering from rosacea with erythematous flushing and burning sensation that is refractory to traditional treatment. There is minimal data on this subgroup of rosacea patients and its potential treatment options. This review aims to explore current medical literature to define characteristics of neurogenic rosacea and its management. We performed a systematic search of PubMed database and identified 6 articles meeting inclusion criteria with a total of 37 patients with suspected neurogenic rosacea. Combination treatments with topicals (eg, metronidazole, brimonidine), as well as oral medications including vascular (eg, beta blockers), psychiatric (eg, diazepam, duloxetine), neurologic (eg, pregabalin, sumatriptan), and antibiotic agents (eg, rifaximin), were often cited to have better outcomes, but this finding was highly variable between patients. There were isolated reports of effective management with onabotulinumtoxinA intradermal injections and endoscopic thoracic sympathectomy treatment. Current literature supports selecting agents aimed at treating the major symptom pattern (eg, erythema, telangiectasias, burning sensation). Neurogenic rosacea treatment: a literature review. Ivanic MG, Oulee A, Norden A, et al. J Drugs Dermatol. 2023;22(6):566-571. doi:10.36849/JDD.7181  .
Collapse
|
2
|
Walia S, Ivanic MG, Jafri ZA, Wu JJ. Assessing the Risk of Omalizumab Add-on Therapy for Chronic Idiopathic Urticaria during the COVID-19 Pandemic. J Clin Aesthet Dermatol 2021; 14:64-65. [PMID: 35096257 PMCID: PMC8794491] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
Amid the current COVID-19 pandemic, there is concern for increased risk of infection while on immunomodulatory therapy. Omalizumab, a monoclonal antibody, is an add-on therapy for the treatment of chronic idiopathic urticaria (CIU) when first line therapy alone fails to achieve appropriate response. Current understanding of the response to COVID-19 infection is largely varied and actively under investigation. In the context of a pandemic, it is important to consider the safety profile of omalizumab as it modulates the immune system. We reviewed data from pivotal Phase III clinical trials investigating omalizumab use in CIU patients with a focus on reported respiratory-related adverse events (AEs) to assess these risks. Results from three phase III trials show that omalizumab adjunct therapy does not significantly increase infection risk and severity.
Collapse
Affiliation(s)
- Shikha Walia
- Dr. Walia is with Lake Erie College of Osteopathic Medicine in Bradenton, Florida
- Dr. Ivanic is with Meharry Medical College in Nashville, Tennessee
- Dr. Jafri is with Arizona College of Osteopathic Medicin in Glendale, Arizona
- Dr. Wu is with the Dermatology Research and Education Foundation in Irvine, California
| | - Mirjana G Ivanic
- Dr. Walia is with Lake Erie College of Osteopathic Medicine in Bradenton, Florida
- Dr. Ivanic is with Meharry Medical College in Nashville, Tennessee
- Dr. Jafri is with Arizona College of Osteopathic Medicin in Glendale, Arizona
- Dr. Wu is with the Dermatology Research and Education Foundation in Irvine, California
| | - Zainab A Jafri
- Dr. Walia is with Lake Erie College of Osteopathic Medicine in Bradenton, Florida
- Dr. Ivanic is with Meharry Medical College in Nashville, Tennessee
- Dr. Jafri is with Arizona College of Osteopathic Medicin in Glendale, Arizona
- Dr. Wu is with the Dermatology Research and Education Foundation in Irvine, California
| | - Jashin J Wu
- Dr. Walia is with Lake Erie College of Osteopathic Medicine in Bradenton, Florida
- Dr. Ivanic is with Meharry Medical College in Nashville, Tennessee
- Dr. Jafri is with Arizona College of Osteopathic Medicin in Glendale, Arizona
- Dr. Wu is with the Dermatology Research and Education Foundation in Irvine, California
| |
Collapse
|
3
|
Naderi-Azad S, Ivanic MG, Walia S, Wu JJ. Atopic Dermatitis Oral Therapies: What Are Patients Learning on YouTube? Cutis 2021; 108:153-157. [PMID: 34826277 DOI: 10.12788/cutis.0346] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Affiliation(s)
- Sheida Naderi-Azad
- Dr. Naderi-Azad is from the University of Toronto, Ontario, Canada. Ms. Ivanic is from Meharry Medical College, Nashville, Tennessee. Ms. Walia is from Lake Erie College of Osteopathic Medicine, Bradenton, Florida. Dr. Wu is from Dermatology Research and Education Foundation, Irvine, California
| | - Mirjana G Ivanic
- Dr. Naderi-Azad is from the University of Toronto, Ontario, Canada. Ms. Ivanic is from Meharry Medical College, Nashville, Tennessee. Ms. Walia is from Lake Erie College of Osteopathic Medicine, Bradenton, Florida. Dr. Wu is from Dermatology Research and Education Foundation, Irvine, California
| | - Shikha Walia
- Dr. Naderi-Azad is from the University of Toronto, Ontario, Canada. Ms. Ivanic is from Meharry Medical College, Nashville, Tennessee. Ms. Walia is from Lake Erie College of Osteopathic Medicine, Bradenton, Florida. Dr. Wu is from Dermatology Research and Education Foundation, Irvine, California
| | - Jashin J Wu
- Dr. Naderi-Azad is from the University of Toronto, Ontario, Canada. Ms. Ivanic is from Meharry Medical College, Nashville, Tennessee. Ms. Walia is from Lake Erie College of Osteopathic Medicine, Bradenton, Florida. Dr. Wu is from Dermatology Research and Education Foundation, Irvine, California
| |
Collapse
|
4
|
Abstract
Biologics have impacted the clinical management of moderate to severe psoriasis. This review article highlights new data findings from phase 3 clinical trials (N=8) published between May 2020 and February 2021. Data on the efficacy of US Food and Drug Administration-approved biologics for treating psoriasis affirms durable skin clearance in the presence of comorbidities and after treatment gaps. This article aims to provide clinicians with up-to-date knowledge on biologic performance focusing on skin disease clearance, time to skin disease clearance, loss of response and relapse, and treatment-emergent adverse events (TEAEs). Recent trial data in this review focus on treatment with IL-17A inhibitors and IL-23 inhibitors.
Collapse
Affiliation(s)
- Mirjana G Ivanic
- Ms. Ivanic is from Meharry Medical College, School of Medicine, Nashville, Tennessee. Ms. Ahn is from the Department of Dermatology, University of California San Diego School of Medicine. Mr. Herndon is from Oakland University William Beaumont School of Medicine, Rochester, Michigan. Dr. Wu is from Dermatology Research and Education Foundation, Irvine, California
| | - Grace S Ahn
- Ms. Ivanic is from Meharry Medical College, School of Medicine, Nashville, Tennessee. Ms. Ahn is from the Department of Dermatology, University of California San Diego School of Medicine. Mr. Herndon is from Oakland University William Beaumont School of Medicine, Rochester, Michigan. Dr. Wu is from Dermatology Research and Education Foundation, Irvine, California
| | - Patrick Herndon
- Ms. Ivanic is from Meharry Medical College, School of Medicine, Nashville, Tennessee. Ms. Ahn is from the Department of Dermatology, University of California San Diego School of Medicine. Mr. Herndon is from Oakland University William Beaumont School of Medicine, Rochester, Michigan. Dr. Wu is from Dermatology Research and Education Foundation, Irvine, California
| | - Jashin J Wu
- Ms. Ivanic is from Meharry Medical College, School of Medicine, Nashville, Tennessee. Ms. Ahn is from the Department of Dermatology, University of California San Diego School of Medicine. Mr. Herndon is from Oakland University William Beaumont School of Medicine, Rochester, Michigan. Dr. Wu is from Dermatology Research and Education Foundation, Irvine, California
| |
Collapse
|
5
|
Abstract
The occurrence of the COVID-19 pandemic has raised new uncertainties for dermatologists and their patients, importantly concerning initiation and continuation of immunosuppressants for dermatological conditions at this time. We review two phase III trials of rituximab, a chimeric CD20 monoclonal antibody, used for the treatment of pemphigus vulgaris. Without specific data studying rituximab use and susceptibility of SARS-CoV-2, we hope to utilize available data in order to assist clinician decision making for rituximab in the context of the pandemic.
Collapse
Affiliation(s)
- Zainab A Jafri
- Arizona College of Osteopathic Medicine, Glendale, AZ, USA
| | - Shikha Walia
- Lake Erie College of Osteopathic Medicine, Bradenton, FL, USA
| | | | - Jashin J Wu
- Dermatology Research and Education Foundation, Irvine, CA, USA
| |
Collapse
|
6
|
Evans AG, Ivanic MG, Botros MA, Pope RW, Halle BR, Glassman GE, Genova R, Al Kassis S. Rejuvenating the periorbital area using platelet-rich plasma: a systematic review and meta-analysis. Arch Dermatol Res 2021; 313:711-727. [PMID: 33433716 DOI: 10.1007/s00403-020-02173-z] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2020] [Revised: 11/03/2020] [Accepted: 12/07/2020] [Indexed: 01/08/2023]
Abstract
Intradermal injection of autologous platelet-rich plasma (PRP) is a non-surgical cosmetic therapy to rejuvenate the periorbital area pathologies of wrinkles, periorbital hyperpigmentation (POH), and photoaging. The past decade has seen the adoption of this novel therapy around the world. This is the first systematic review and meta-analysis evaluating PRP treatment of periorbital pathologies. This is a PRISMA compliant review that includes a comprehensive search of the databases Cochrane Library, Ovid Medline, Ovid Embase, and clinicaltrials.gov. The search was performed in June 2019 to obtain all peer-reviewed articles published in English that describe the application of PRP to periorbital pathologies. A meta-analysis of patient satisfaction was performed for randomized controlled trials. Nineteen studies treating 455 patients (95% female, age range 28-60) were included. Studies were categorized based on reported outcomes: wrinkles (11 studies), POH (7 studies), and photoaging (6 studies). Patients were treated a mean of 3 times (range 1-8) in mean intervals of 23 days (range 14-56 days). Follow-up averaged 3 months (range 1-6 months). Meta-analysis of 3 randomized controlled clinical trials (RCTs) shows that patients treated with PRP have increased satisfaction above controls of saline, platelet-poor plasma, mesotherapy, and as an adjunct to laser therapy (overall effect p = 0.001, heterogeneity I2 = 64%). PRP treatment of periorbital area pathologies results in histologic improvements of photoaging, subjective satisfaction score increases, and blind evaluator assessments of rejuvenated skin appearance. Future studies are needed to address limitations of the current literature and should include long-term follow-up, delineation of the POH etiology that is treated, RCTs with low risk of bias, and be absent conflicts of interest or industry sponsors.Trial registration: Prospero Systematic Review Registration ID: CRD42019135968.
Collapse
Affiliation(s)
- Adam G Evans
- Meharry Medical College, 1005 Dr DB Todd Jr Blvd, Nashville, TN, 37208, USA. .,Division of Plastic and Reconstructive Surgery, Department of Surgery, Washington University School of Medicine, 660 S. Euclid Ave, St. Louis, MO, 63110, USA.
| | - Mirjana G Ivanic
- Meharry Medical College, 1005 Dr DB Todd Jr Blvd, Nashville, TN, 37208, USA.,Department of Plastic Surgery, Vanderbilt University Medical Center, D-4207 Medical Center North, 1211 Medical Center Drive, Nashville, TN, 37212, USA
| | - Mina A Botros
- Meharry Medical College, 1005 Dr DB Todd Jr Blvd, Nashville, TN, 37208, USA
| | - Rand W Pope
- Vanderbilt University School of Medicine, 1161 21st Ave South, Nashville, TN, 37232, USA
| | - Briana R Halle
- Vanderbilt University School of Medicine, 1161 21st Ave South, Nashville, TN, 37232, USA
| | - Gabriella E Glassman
- Department of Plastic Surgery, Vanderbilt University Medical Center, D-4207 Medical Center North, 1211 Medical Center Drive, Nashville, TN, 37212, USA
| | - Rafaella Genova
- University of Tennessee Health Science Center, 910 Madison Ave, Memphis, TN, 38163, USA
| | - Salam Al Kassis
- Department of Plastic Surgery, Vanderbilt University Medical Center, D-4207 Medical Center North, 1211 Medical Center Drive, Nashville, TN, 37212, USA
| |
Collapse
|
7
|
Ivanic MG, Naderi-Azad S, Walia S, Han G, Wu JJ. Management of psoriasis with biologics in clinical practice: an update for 2020. Cutis 2020; 106:21-24. [PMID: 33104096 DOI: 10.12788/cutis.0035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
This article aims to address updates on recent clinical trial findings (April 2019 to April 2020) regarding biologic therapy initiation and maintenance for adult patients. Prescribers should use this update as guidance for determining the appropriate biologic class based on patient characteristics and for approaching biologic-experienced patients with refractory psoriasis. This update also may serve as a reference for the recommended dosing regimens of the 11 approved biologics.
Collapse
Affiliation(s)
| | | | - Shikha Walia
- Lake Erie College of Osteopathic Medicine, Pennsylvania, USA
| | - George Han
- Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - Jashin J Wu
- Dermatology Research and Education Foundation, Irvine, California, USA
| |
Collapse
|
8
|
Evans AG, Mwangi JM, Pope RW, Ivanic MG, Botros MA, Glassman GE, Pearce FB, Kassis S. Platelet-rich plasma as a therapy for androgenic alopecia: a systematic review and meta-analysis. J DERMATOL TREAT 2020; 33:498-511. [DOI: 10.1080/09546634.2020.1770171] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Affiliation(s)
- Adam G. Evans
- School of Medicine, Meharry Medical College, Nashville, TN, USA
| | - James M. Mwangi
- School of Medicine, Meharry Medical College, Nashville, TN, USA
| | - Rand W. Pope
- School of Medicine, Vanderbilt University, Nashville, TN, USA
| | | | - Mina A. Botros
- School of Medicine, Meharry Medical College, Nashville, TN, USA
| | - Gabriella E. Glassman
- Department of Plastic Surgery, Vanderbilt University Medical Center, Nashville, TN, USA
| | - F. Bennett Pearce
- Department of Plastic Surgery, Vanderbilt University Medical Center, Nashville, TN, USA
| | - Salam Kassis
- Department of Plastic Surgery, Vanderbilt University Medical Center, Nashville, TN, USA
| |
Collapse
|
9
|
Walia S, Ivanic MG, Jafri ZA, Wu JJ. Skin cancer screening and prevention during the COVID-19 pandemic. Cutis 2020; 107:41-42;53. [PMID: 33651865 DOI: 10.12788/cutis.0157] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Affiliation(s)
- Shikha Walia
- Lake Erie College of Osteopathic Medicine, Bradenton, Florida, USA
| | | | | | - Jashin J Wu
- Dermatology Research and Education Foundation, Irvine, California, USA
| |
Collapse
|